Atika Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Atika Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-305,000	Closed	-$5.42M	–	110
2018 Q3	$5.42M	Buy	305,000 +10,000	+3%	+$172K	0.97%	36
2018 Q2	$4.07M	Buy	+295,000	New	+$3.5M	0.78%	48

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Atika Capital Management's ECYT Position: Q4 2018 in Review

Atika Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 305,000 shares — an estimated $5.42M sold.

Atika Capital Management first reported a position in ECYT in Q2 2018 and held it in 2 quarters. The position peaked at $5.42M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Atika Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Atika Capital Management sold 305,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $5.42M.
Atika Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
Atika Capital Management's Endocyte, Inc. Common Stock position peaked at $5.42M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Atika Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.